BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

772 related articles for article (PubMed ID: 20697079)

  • 1. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.
    Rischin D; Young RJ; Fisher R; Fox SB; Le QT; Peters LJ; Solomon B; Choi J; O'Sullivan B; Kenny LM; McArthur GA
    J Clin Oncol; 2010 Sep; 28(27):4142-8. PubMed ID: 20697079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
    Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
    J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p16 Expression as a predictive biomarker of hypoxic cell-sensitizing agents in oropharyngeal cancer.
    Chung CH; Raben D
    J Clin Oncol; 2010 Sep; 28(27):4103-4. PubMed ID: 20697096
    [No Abstract]   [Full Text] [Related]  

  • 4. p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status.
    Lewis JS; Thorstad WL; Chernock RD; Haughey BH; Yip JH; Zhang Q; El-Mofty SK
    Am J Surg Pathol; 2010 Aug; 34(8):1088-96. PubMed ID: 20588174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
    Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
    Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma.
    Ukpo OC; Flanagan JJ; Ma XJ; Luo Y; Thorstad WL; Lewis JS
    Am J Surg Pathol; 2011 Sep; 35(9):1343-50. PubMed ID: 21836494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: a comparison of antibody clones using patient outcomes and high-risk human papillomavirus RNA status.
    Shelton J; Purgina BM; Cipriani NA; Dupont WD; Plummer D; Lewis JS
    Mod Pathol; 2017 Sep; 30(9):1194-1203. PubMed ID: 28621317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk profiling based on p16 and HPV DNA more accurately predicts location of disease relapse in patients with oropharyngeal squamous cell carcinoma.
    Rasmussen JH; Grønhøj C; Håkansson K; Friborg J; Andersen E; Lelkaitis G; Klussmann JP; Wittekindt C; Wagner S; Vogelius IR; von Buchwald C
    Ann Oncol; 2019 Apr; 30(4):629-636. PubMed ID: 30657857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of p16 and p53 expression in oropharyngeal squamous cell carcinomas.
    Shinohara S; Kikuchi M; Tona R; Kanazawa Y; Kishimoto I; Harada H; Imai Y; Usami Y
    Jpn J Clin Oncol; 2014 Mar; 44(3):232-40. PubMed ID: 24470584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus in oropharyngeal squamous cell carcinomas in Korea: use of G1 cycle markers as new prognosticators.
    Park WS; Ryu J; Cho KH; Choi MK; Moon SH; Yun T; Chun BS; Lee GK; Ahn HJ; Lee JH; Vermeer P; Jung YS
    Head Neck; 2012 Oct; 34(10):1408-17. PubMed ID: 22052559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-based p16 and HPV positivity rates in oropharyngeal cancer in Southeast Scotland.
    Wells LA; Junor EJ; Conn B; Pattle S; Cuschieri K
    J Clin Pathol; 2015 Oct; 68(10):849-52. PubMed ID: 26152733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas.
    Sedaghat AR; Zhang Z; Begum S; Palermo R; Best S; Ulmer KM; Levine M; Zinreich E; Messing BP; Gold D; Wu AA; Niparko KJ; Kowalski J; Hirata RM; Saunders JR; Westra WH; Pai SI
    Laryngoscope; 2009 Aug; 119(8):1542-9. PubMed ID: 19522004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.
    Leeman JE; Li JG; Pei X; Venigalla P; Zumsteg ZS; Katsoulakis E; Lupovitch E; McBride SM; Tsai CJ; Boyle JO; Roman BR; Morris LGT; Dunn LA; Sherman EJ; Lee NY; Riaz N
    JAMA Oncol; 2017 Nov; 3(11):1487-1494. PubMed ID: 28542679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Keratinizing-type squamous cell carcinoma of the oropharynx: p16 overexpression is associated with positive high-risk HPV status and improved survival.
    Cai C; Chernock RD; Pittman ME; El-Mofty SK; Thorstad WL; Lewis JS
    Am J Surg Pathol; 2014 Jun; 38(6):809-15. PubMed ID: 24698966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of p16 levels and pre-radiotherapy factors predicts outcome in patients treated for oropharyngeal carcinoma.
    Bar-Ad V; Wang ZX; Leiby B; Tuluc M
    J BUON; 2013; 18(4):982-8. PubMed ID: 24344027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
    Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
    Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials.
    Jordan RC; Lingen MW; Perez-Ordonez B; He X; Pickard R; Koluder M; Jiang B; Wakely P; Xiao W; Gillison ML
    Am J Surg Pathol; 2012 Jul; 36(7):945-54. PubMed ID: 22743284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
    Fakhry C; Westra WH; Li S; Cmelak A; Ridge JA; Pinto H; Forastiere A; Gillison ML
    J Natl Cancer Inst; 2008 Feb; 100(4):261-9. PubMed ID: 18270337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor cell anaplasia and multinucleation are predictors of disease recurrence in oropharyngeal squamous cell carcinoma, including among just the human papillomavirus-related cancers.
    Lewis JS; Scantlebury JB; Luo J; Thorstad WL
    Am J Surg Pathol; 2012 Jul; 36(7):1036-46. PubMed ID: 22743286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.